Table 1.
Baseline characteristics of patients enrolled in the study
| Characteristics | RTX + rhTPO (n = 77) | RTX (n = 38) |
|---|---|---|
| Age (y), median (range) | 42 (13-82) | 42.5 (12-68) |
| Female/male, % (n) | 64.9 (50)/35.1 (27) | 65.8 (25)/34.2 (13) |
| Baseline platelet count (109/L), median (range) | 9 (0-30) | 12.5 (2-30) |
| ITP duration (mo) | ||
| Median | 12.5 | 11 |
| IQR | 7, 22 | 6, 23 |
| Range | 3-72 | 3-65 |
| Previous therapies, % (n) | ||
| Dexamethasone | 55.8 (43) | 50.0 (19) |
| Prednisone | 40.3 (31) | 34.2 (13) |
| Methylprednisolone | 14.3 (11) | 21.0 (8) |
| IVIG | 19.5 (15) | 18.4 (7) |
| Vincristine | 6.5 (5) | 0 |
| rhTPO | 7.8 (6) | 5.3 (2) |
| Cyclosporin | 3.9 (3) | 2.6 (1) |
| Danazol | 6.5 (5) | 10.5 (4) |
| Azathioprine | 1.3 (1) | 0 |
| Herbs | 10.4 (8) | 7.9 (3) |
| Splenectomy* | 11.7 (9) | 7.9 (3) |
| Bleeding score†, % (n) | ||
| 0 | 13.0 (10) | 15.8 (6) |
| 1 | 58.4 (45) | 55.3 (21) |
| 2 | 20.8 (16) | 21.0 (8) |
| 3 | 6.5 (5) | 7.9 (3) |
| 4 | 1.3 (1) | 0 |
IQR, interquartile range; IVIG, intravenous immunoglobulin.
*
The median time (range) from splenectomy to enrollment of these 12 patients was 7 months (3-22 months).
†
Bleeding score was at baseline.